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Sweden was the first country to establish a nationwide breast cancer screening service. We used the Swedish Family-Cancer
Database to evaluate the risk of invasive carcinoma after in situ carcinoma of the breast. Risk estimates for contralateral and ipsilateral
invasive malignancies following age and histology specific in situ breast carcinomas were calculated using Poisson’s regression analysis.
The agreement between concordant and discordant morphologies of invasive and in situ breast cancer was measured using the kappa
statistic. Women with in situ breast cancer showed a relative risk of 2.03 for contralateral and 3.94 for ipsilateral invasive breast
cancer. The risk was higher for in situ carcinomas diagnosed before the age of 50 years and after lobular in situ breast cancers. A
comparison of the risks during the past decades suggested that the risk of ipsilateral breast cancer has increased in Sweden but that of
contralateral breast cancer has remained unchanged. In situ and the subsequent invasive breast cancers did not seem to share their
morphologies.
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The most common morphologies of carcinoma in situ of the breast
are ductal (DCIS) and lobular carcinoma (LCIS). In Sweden, the
incidence of DCIS has increased since the introduction of
mammographic screening, representing now 15–20% of all breast
malignancies, compared with 5% of the cases in prescreening era
(Pinder and Ellis, 2003). The incidence of LCIS has also increased,
but appreciably slower than that of DCIS (Ernster et al, 1996). In
addition to the different incidence patterns, mostly due to
mammographic characteristics, DCIS is regarded as a local
precursor of invasiveness, while LCIS is merely considered a
general risk factor for developing invasive carcinoma, including a
contralateral malignancy (Claus et al, 2003; Page, 2004). The
estimated risks of invasive breast cancer after in situ carcinoma are
heterogeneous in the literature: DCIS has been associated with a
four- to 10-fold risk increment; the estimates of the relative risk
(RR) after LCIS vary from 2 to 11 (Page et al, 2000; Warnberg et al,
2000).
Sweden has been the first country that implemented a nation-
wide mammographic screening. The first service was started in
year 1986 and it was extended to a complete national coverage by
year 1997 (Olsson et al, 2000). One consequence of screening has
been an earlier detection of breast cancer (Zahl et al, 2004). The
conservative breast surgery may have also influenced the clinical
course and prognosis of breast cancer (Kestin et al, 2000). The aim
of the present study was to evaluate the risk of invasive breast
carcinoma after in situ carcinoma in Sweden. The estimation was
based on cancers diagnosed between 1993 and 2000, thus taking
into account the possible impact of screening and recent advances
in management of in situ breast cancers. Risk estimates were
derived for contralateral and ipsilateral invasive malignancies
following age- and histology-specific in situ breast carcinomas.
The change in the risk of invasive carcinoma after in situ breast
cancer during the last 20 years in Sweden was also explored.
MATERIALS AND METHODS
The Swedish Family-Cancer Database was created in the mid-1990s
by linking census information, death notifications and the
administrative family register to the Swedish Cancer Registry at
Statistics Sweden (Hemminki, 2001; Hemminki et al, 2001). The
Database was updated at the end of 2002 to include more than 10
million individuals. The present analysis considered diagnoses
made between 1993 and 2000 and included 3802 in situ breast and
35480 invasive breast cancers in a population of five million
women. The Swedish Cancer Registry is based on compulsory
reports of individual cases provided by clinicians/pathologists or
cytologists and is considered to have almost 100% completeness
(The National Board of Health and Welfare Stockholm, 2002). The
incidence of cancer in the Database is similar to the incidence in
the Cancer Registry (Hemminki et al, 2001; Plna and Hemminki,
2001). Four-digit diagnostic codes from the seventh revision of the
International Classification of Diseases (ICD-7) and subsequent
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breast was indicated by ICD-7 code 170. Histology was recor-
ded according to the Systemized Nomenclature of Medicine
(SNOMED). Invasive breast cancers were classified as: ductal
carcinoma (SNOMED code 85003), lobular carcinoma (85203) and
comedo carcinoma (85013). In situ breast cancers were also
classified in three categories: ductal carcinoma (85002), lobular
carcinoma (85202) and comedo carcinoma (85012). Breast cancer
is often of mixed morphology at presentation and only the main
type was recorded in the Swedish Cancer Registry (Harris et al,
1993). Invasive breast cancers diagnosed after in situ malignancies
in the other breast were classified as contralateral, but as ipsilateral
if they occurred in the same breast. Only invasive cancers
diagnosed at least 1 month after diagnosis of the in situ breast
carcinoma were included in the present study. Incidence rates of
histology-specific breast cancers were standardised for age
according to the European population. Variations in incidence
rates from 1993 to 2000 were studied by log linear regression
analyses based on the maximum-likelihood method (Figure 1).
Follow-up began at the age of 21 years (earliest age at diagnosis
of invasive breast cancer), the date of immigration, the date of
diagnosis of in situ breast cancer or 1 January 1993, whichever
occurred last. Follow-up ended at diagnosis of the first primary
malignancy, death date, emigration date or 31 December 2000,
whichever occurred first. Person-years and cases of invasive breast
cancer were counted and grouped by age, family history, age at
first birth and the presence or absence of in situ breast cancer. A
Poisson regression analysis was applied to the data using the
Genmod procedure of the SAS program (SAS/STAT
s User’s guide,
1999). The results are shown as an RR, with 95% confidence limits
(95% CI). Risk estimates were also calculated for the periods
1981–1990, 1991–1995 and 1996–2000 in order to investigate
possible changes during the last 20 years in Sweden. Differences in
the time of follow-up and age of the women among the three
periods were taken into account by indirect standardisation before
Poisson’s regression, using the period 1996–2000 as reference.
The kappa statistic was used as a measure of agreement between
concordant and discordant morphologies of invasive and in situ
breast cancer. Kappa takes values between  1 and 1, where 0
indicates no determination and  1 or 1 would indicate that the
morphology of the invasive carcinoma is completely determined
by the histology of the prior in situ carcinoma. Values of the kappa
statistic between 0.40 and 0.60 would suggest a moderate
concordance.
RESULTS
The incidence rate of invasive ductal cancer increased in the
period 1993–2000 from 46.8 to 66.1/100000 (þ5.1% per year) and
invasive lobular cancer showed an increase from 9.0 to 14.2/
100000 (þ7.1% per year). A striking decrease was found for the
comedo histology, with incidence rates from 6.1 to 1.1/100000
( 18.6% per year). In situ ductal cancer increased from 7.2 to 8.7/
100000 (þ3.1% per year) and, interestingly, the incidence of in
situ lobular cancer remained constant (1.6/100000). In situ
comedo cancer showed a decreasing incidence rate from 1.7 to
0.8/100000 ( 11.1% per year).
The results of the Poisson regression analysis for contralateral
breast cancer are presented in Table 1. The diagnosis of in situ
breast carcinoma resulted in a two-fold increase in the risk of
invasive cancer in the contralateral breast; the increase was
particularly high if the in situ breast lesion was diagnosed before
the age of 50 years. The risk increased with the time after diagnosis
of the in situ carcinoma, although the increment was not
statistically significant. The lobular histology of in situ breast
carcinoma was associated with the highest risk for contralateral
invasive breast cancer. The diagnosis of in situ carcinoma resulted
in an RR of 3.94 for invasive ipsilateral cancer (Table 2). Comedo
in situ carcinoma was associated with the highest risk of ipsilateral
invasive breast cancer (RR¼5.02).
The risks of contralateral invasive cancer after in situ breast
cancer slightly increased during the period 1991–1995 and it
decreased thereafter, but were not statistically significant
(Figure 2A). In contrast, the risks of ipsilateral invasive breast
cancer after in situ breast cancer in 1991–1995 and 1996–2000
were two times higher than in 1981–1990 (Figure 2B); the risk
differences were statistically significant. The increase in the risk of
ipsilateral breast cancer was mostly associated with in situ
carcinomas diagnosed at ages 50–60 years (results not shown).
Table 3 shows kappa measures of agreement between con-
cordant in situ and invasive morphologies. Kappa values for all
concordant and discordant histologies (results not shown for
discordant histologies) were lower than 0.40, thus suggesting that
the histology of the invasive cancers was not determined by the
morphology of the preceding in situ carcinoma.
DISCUSSION
The treatment for the first breast cancer, the intense medical
follow-up and the self-observation of the patient complicate the
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Figure 1 Trends in incidence rates of invasive (A) and in situ breast
cancer (B) according to histologic subtype, based on the Swedish Family-
Cancer Database. Incidence rates are adjusted for age (European standard).
The mean annual increase or decrease is presented at the curve. The
numbers of observed cases are presented for each year.
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at risk for the first cancer, but only one of them is at risk for
ipsilateral or for contralateral breast cancer. Treatment, follow-up
and definition differences have probably contributed to the
incongruent results for invasive breast cancer after in situ
carcinoma in the literature (Chen et al, 1999). The RRs shown in
the present study were calculated after dividing the second breast
cancers into contralateral and ipsilateral breast cancers.
All in situ breast carcinomas are premalignant, being possible
precursors to invasive disease capable of metastasis (Dupont and
Page, 1985; Page et al, 1985, 2000; Page and Dupont, 1990; London
et al, 1992). The potential for progression to invasive cancer has
been measured in earlier studies (Franceschi et al, 1998; Ottesen
et al, 2000; Crocetti et al, 2001; Warnberg et al, 2001). However, the
number of cases analysed previously was small. One study
considered breast cancers in the period 1980–1992, that is, before
and during the establishment of screening services in Sweden
(Warnberg et al, 1999). Earlier diagnosis due to screening and
recent advances in the treatment of in situ carcinoma have resulted
in better survival rates for patients and a higher incidence for
invasive carcinoma. An advantage of the present study was the
adjustment for age, family history and parity in the Poisson
regression analyses. Unfortunately, information on possible
confounders such as treatment received, use of contraceptives
and stage of the cancer or tumour size was not available.
Table 1 Contralateral invasive breast cancer subsequent to in situ
carcinoma of breast analysed in Poisson’s regression model
RR¼relative risk; CI¼confidence interval. Data were additionally adjusted for age,
family history, parity and age at first birth. Bold¼the RR was statistically higher than
1.00.
Table 2 Ipsilateral invasive breast cancer subsequent to in situ carcinoma
of breast analysed in Poisson’s regression model
RR¼relative risk; CI¼confidence interval. Data were additionally adjusted for age,
family history, parity and age at first birth. Bold¼the RR was statistically higher than
1.00.
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Figure 2 Relative risk of contralateral (A) and ipsilateral (B) invasive
breast carcinoma subsequent to in situ breast carcinoma for different
periods.
Risk of invasive carcinoma after in situ breast carcinoma
R Rawal et al
164
British Journal of Cancer (2005) 92(1), 162–166 & 2005 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yThe increased incidence of invasive ductal and lobular breast
cancers found in the present study was similar to previous reports
(Levi et al, 1997; Li et al, 2003; Verkooijen et al, 2003). The
reduction in the incidence of comedo breast cancer is probably
attributable to modifications in pathological classification criteria.
The incidence of DCIS increased in the period 1993–2000, which
was to a small extent due to the reclassification of comedo in situ
carcinomas as DCIS. In contrast, the incidence of LCIS did not
change. Earlier reports have shown increases in the incidence of
DCIS and LCIS (Simon et al, 1993; Choi et al, 1996; Levi et al,
1997). The different incidence patterns found for DCIS and LCIS in
the present study may be partly attributable to the low calcification
of lobular tumours, which hampers their detection by mammo-
graphy.
In situ breast carcinoma diagnosed before the age of 50 years
was associated with the highest risk of invasive cancer, the
difference from other age groups was even statistically significant
for ipsilateral breast cancer. In patients with mammographically
detected ductal carcinoma in situ, treated with breast-conserving
therapy, young patient age has been reported to be a risk factor for
local recurrence (Kestin et al, 2000). Our results were similar to
earlier studies, which have shown higher risks for invasive breast
cancer in women with in situ cancer diagnosed at young ages
(Franceschi et al, 1998; Crocetti et al, 2001; Warnberg et al, 2001;
Claus et al, 2003). The risk of invasive breast cancer increased with
the time after diagnosis of in situ carcinoma, but the number of
cases analysed was small and the trend was not statistically
significant. Our data agree with earlier results, that the highest risk
of invasive cancer is reached after 42 to 60 months after diagnosis
of in situ lesions. (Franceschi et al, 1998; Ottesen et al, 2000;
Warnberg et al, 2000, 2001; Crocetti et al, 2001).
The risk of invasive cancer in the contralateral and ipsilateral
breasts was higher after lobular than after ductal carcinoma in situ.
Our results therefore disagree with the report suggesting that this
risk was higher after DCIS than after LCIS (Warnberg et al, 2000).
A higher incidence of DCIS due to screening may have diluted the
risk of the subsequent invasive breast cancer, whereas the
incidence of LCIS and its corresponding risk seem to have been
only slightly modified.
The estimated risk of ipsilateral invasive cancer after in situ
lesions was almost two times higher than the corresponding risk of
contralateral breast cancer. This risk difference was only found
after 1991, and was statistically significant for the period 1996–
2000. Breast-conserving surgery became the treatment of choice
for early breast cancer in Sweden during the 1980s, especially in
areas with population-based screening (Fredriksson et al, 2001).
The proportion of women receiving conservative surgery increased
from 7% in 1980 to 51% in 1996 (Lindqvist et al, 2002).
Inadequately treated in situ breast carcinoma, for example,
insufficient margin control, may have contributed to the observed
risk increase (Yau et al, 2002; Fredriksson et al, 2003; Kerlikowske
et al, 2003; Khan and Newman, 2004).
The suggestion of previous studies that in situ and subsequent
invasive cancers share morphological features (Habel et al, 1997;
Franceschi et al, 1998) could not be confirmed in the present
study. However, we found the highest concordance for the lobular
histology, in agreement with earlier studies, which showed that
LCIS is often followed by lobular invasive breast cancer (Lishman
and Lakhani, 1999; Fisher et al, 2004). The present study is
congruent with earlier analyses on the genetic determination of the
morphology of invasive breast cancer based on the Swedish
Family-Cancer Database (Hemminki and Granstrom, 2002).
We conclude that the incidence of in situ carcinoma of the
breast has increased in the last decade and that the introduction of
screening and new treatments in Sweden seems to have modified
the pattern of risk of invasive cancer after in situ carcinoma. The
risk of invasive cancer in the ipsilateral breast has increased.
Women with LCIS are at higher risk of invasive breast cancer than
women with DCIS. The risks estimated in this study may help in
clinical counselling.
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